Debbie Rigby takes a look at the latest in research news
This review discusses the potential future position of LAMAs in clinical practice by considering the continuously evolving evidence. Prominence is given to tiotropium, the only LAMA supported by a structured clinical trial program in asthma to date, while also considering other recommended treatment options for patients with uncontrolled asthma. The importance of effective patient/caregiver–clinician communication and shared decision-making in enhancing treatment adherence is also highlighted.
Therapeutics and Clinical Risk Management 2019;15:473-85.
A systematic review and network meta-analysis of clinical outcomes of 84 trials has concluded that behavioral therapy, alone or in combination with other interventions, is generally more effective than pharmacologic therapies alone in treating both stress and urgency UI. Most nonpharmacologic and pharmacologic interventions are more likely than no treatment to improve UI outcomes.
Ann Intern Med. 2019.
Individuals using statins may be at higher risk for hyperglycaemia, insulin resistance and eventually type 2 diabetes. Rigorous preventive strategies such as glucose control and weight reduction in patients when initiating statin therapy might help minimize the risk of diabetes.
Br J Clin Pharmacol. 2019;1–10.
This study demonstrated that integration of the DBI Calculator© into HMR is a feasible and useful method to prompt deprescribing of anticholinergic and sedative medications in older adults. The median DBI of intervention patients was reduced from 0.82 to 0.67 (p = 0.014), demonstrating the deprescribing of anticholinergic and sedative medications in this patient cohort.
Ther Adv Drug Saf 2019;10:1–15.